Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy
Alexandra Lainé, Travis T. Sims, Olivia Le Saux, Isabelle Ray‐Coquard, Robert L. Coleman
Topics & Concepts
MedicineBevacizumabOvarian cancerOncologyInternal medicineIntensive care medicineClinical trialOlaparibDiseaseFirst line treatmentCancerGynecologyPoly ADP ribose polymeraseChemotherapyPolymeraseChemistryBiochemistryGeneOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapyViral-associated cancers and disorders